SLC5A2 and atrial fibrillation: In a meta‐analysis that included various studies of heart and kidney failure patients (the EMPA‐REG OUTCOME trial, CANVAS, CANVAS‐R, the DECLARE‐TIMI 58 trial, CREDENCE, DAPA‐HF, VERTIS‐CV and DAPA‐CKD), Okunrintemi and colleagues showed a significantly lower incidence of AF in individuals taking SGLT2 inhibitors versus placebo (relative risk 0.79, 95% CI 0.67–0.93).100